NephCure Breaks Down Travere's Interim FSGS DUPLEX Results

NephCure's Nurse Kristen Hood and Kylie Winkler discuss Travere's Therapeutics achievement of interim proteinuria endpoint in the ongoing Phase 3 DUPLEX study of Sparsentan in Focal Segmental Glomerulosclerosis (FSGS).
Learn more about the trial currently underway, why this is such a crucial step for patients with rare kidney diseases, and what potential treatments this could lead to in just a few short years!
Read the full press release here: ir.travere.com/news-releases/...

[@muqeetamjad8025]

I am a FSGS patient too...

[@umangsubedi1029]

Its great news to hear

[@musicani8735]

Its really a great .

[@ladygeneviere]

I just hope it reaches us down under and that it will be covered by the PBS. Otherwise, it's just a "nice to have" drug because low income people (who are affected by FSGS) can't afford it.

[@musicani8735]

When this medicine will come in the market.?

[@007punitsingh]

Is it reverse ckd

[@007punitsingh]

Is it reverse ckd...??

[@sandiefung9037]

Is there any side effect known in Sparsentan?

[@ladygeneviere]

Says there is a very high likelihood of hypotension, dizziness, edema, nausea, and gastrointestinal side effects.

[@hafizahafiza9454]

It is for cronic kidney disease